EP1451209A2 - Tetra-,penta-,hexa- and heptapeptides having antiangiogenic activity - Google Patents
Tetra-,penta-,hexa- and heptapeptides having antiangiogenic activityInfo
- Publication number
- EP1451209A2 EP1451209A2 EP02789322A EP02789322A EP1451209A2 EP 1451209 A2 EP1451209 A2 EP 1451209A2 EP 02789322 A EP02789322 A EP 02789322A EP 02789322 A EP02789322 A EP 02789322A EP 1451209 A2 EP1451209 A2 EP 1451209A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- arg
- ile
- pronhch
- nva
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to methods of inhibiting angiogenesis, methods of treating cancer, and compounds having activity useful for treating conditions which arise from or are exacerbated by angiogenesis. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds.
- Angiogenesis is the fundamental process by which new blood vessels are formed and is essential to a variety of normal body activities (such as reproduction, development and wound repair). Although the process is not completely understood, it is believed to involve a complex interplay of molecules which both stimulate and inhibit the growth of endothelial cells, the primary cells of the capillary blood vessels. Under normal conditions these molecules appear to maintain the microvasculature in a quiescent state (i.e., one of no capillary growth) for prolonged periods that may last for weeks, or in some cases, decades. However, when necessary, such as during wound repair, these same cells can undergo rapid proliferation and turnover within as little as five days.
- angiogenesis is a highly regulated process under normal conditions, many diseases (characterized as “angiogenic diseases") are driven by persistent unregulated angiogenesis. Otherwise stated, unregulated angiogenesis may either cause a particular disease directly or exacerbate an existing pathological condition. For example, the growth and metastasis of solid tumors have been shown to be angiogenesis-dependent. Based on these findings, there is a continuing need for compounds which demonstrate antiangiogenic activity due to their potential use in the treatment of various diseases such as cancer. Peptides having angiogenesis inhibiting properties have been described in commonly-owned WO01/38397, WO01/38347, WO99/61476, and U.S. Patent Application Ser. No. 09/915,956. However, it would be desirable to prepare antiangiogenic compounds having improved profiles of activity and smaller size.
- the present invention relates to a novel class of compounds having angiogenesis-inhibiting properties.
- the invention provides tetra-, penta-, hexa-, and heptapeptides with enhanced properties of angiogenesis inhibition.
- the present invention provides a compound of formula (I) Xaa ⁇ -Xaa 2 -Xaa 3 -Xaa 4 -Xaa 5 -Xaa 6 -Xaa 7 -Xaa 8 (I), (SEQ ID NO: 1) or a therapeutically acceptable salt thereof, wherein
- Xaaj is selected from the group consisting of hydrogen and R-(CH ) n -C(O)-, wherein n is an integer from 0 to 8 and R is selected from the group consisting of alkoxy, alkyl, amino, aryl, carboxyl, cycloalkenyl, cycloalkyl, and heterocycle;
- Xaa 8 is selected from the group consisting of D-alanylamide, azaglycylamide, glycylamide, hydroxyl, D-lysyl(N-epsilon-acetyl)amide, a group represented by the formula
- R is selected from the group consisting of hydrogen, alkyl, cycloalkenyl, and cycloalkyl; R is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl,
- R is other than alkoxy or hydroxyl
- R is selected from the group consisting of hydrogen, cycloalkenyl, cycloalkyl, and hydroxyl
- Xaa6 is D-alloisoleucyl
- Xaa is threonyl
- Xaa 8 is hydroxyl
- the present invention provides a compound of formula (II) Xaa ⁇ -Xaa 2 -Xaa 3 -Xaa 4 -Xaa 5 -Xaa 6 -Xaa 7 -Xaa 8 (II), (SEQ ID NO:2) or a therapeutically acceptable salt thereof, wherein Xaaj is absent or R-(CH 2 ) n -C(O)-, wherein n is an integer from 0 to 8 and R is selected from the group consisting of alkoxy, alkyl, amino, aryl, carboxyl, cycloalkenyl, cycloalkyl, and heterocycle;
- Xaa 2 is selected from the group consisting of ⁇ -alanyl, D-alanyl, D-alloisoleucyl, D- allylglycyl, D-4-chlorophenylalanyl, D-citrullyl, D-3-cyanophenylalanyl, D-homophenylalanyl, D- homoseryl, isoleucyl, D-isoleucyl, D-leucyl, N-methyl-D-leucyl, D-norleucyl, D-norvalyl, D- penicillaminyl, D-phenylalanyl, D-prolyl, D-seryl, D-thienylalanyl, and D-threonyl;
- Xaa 3 is selected from the group consisting of allothreonyl, aspartyl, glutaminyl, D- glutaminyl, N-methylglutaminyl, glycyl, histidyl, homoseryl, isoleucyl, lysyl(N-epsilon-acetyl), methionyl, seryl, N-methylseryl, threonyl, D-threonyl, tryptyl, tyrosyl, and tyrosyl(O-methyl);
- Xasi f is selected from the group consisting of arginyl, D-arginyl, citrullyl, histidyl, lysyl, lysyl(N-epsilon-isopropyl), ornithyl, and 3-(3-pyridyl)alanyl;
- Xaa is absent or selected from the group consisting of N-methyl-D-alanyl, 2-aminobutyryl,
- Xaa 8 is selected from the group consisting of D-alanylamide, azaglycylamide, glycylamide, hydroxyl, D-lysyl(N-epsilon-acetyl)amide, a group represented by the formula -NH-(CH 2 ) n -
- R is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocycle,
- the present invention provides a compound of formula (II), or a therapeutically acceptable salt thereof, wherein Xaa 2 is selected from the group consisting of ⁇ - alanyl, D-alloisoleucyl, D-4-chlorophenylalanyl, D-homophenylalanyl, D-leucyl, D-penicillaminyl, and D-prolyl; and Xaaj, Xaa 3 , Xaa 4 , Xaas, Xaa ⁇ , Xaa 7 , and Xaa 8 are as described for formula (II).
- the present invention provides a compound of formula (II), or a therapeutically acceptable salt thereof, wherein Xaa is D-isoleucyl, Xaa 3 is selected from the group consisting of allothreonyl, aspartyl, glutaminyl, lysyl(N-epsilon-acetyl), methionyl, seryl, and tyrosyl, and Xaa., Xaa-j, Xaas, X a ⁇ s, Xaa 7 , and Xaa 8 are as described for formula (II).
- the present invention provides a compound of formula (II), or a therapeutically acceptable salt thereof, wherein Xaa 2 is D-isoleucyl, Xaa 3 is threonyl, Xaa is selected from the group consisting of arginyl, glutaminyl, D-glutaminyl, norleucyl, norvalyl, N-methylnorvalyl, seryl, and tryptyl, and Xaaj, Xaas, X ag, Xaa , and Xaa 8 are as described for formula (II).
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (II), or a therapeutically acceptable salt thereof, in combination with a therapeutically acceptable carrier.
- the present invention provides a method of inhibiting angiogenesis in a mammal in recognized need of such treatment comprising administering to the mammal a therapeutically acceptable amount of a compound of formula (II) or a therapeutically acceptable salt thereof.
- the present invention provides a method of treating cancer in a mammal in recognized need of such treatment comprising administering to the mammal a therapeutically acceptable amount of a compound of formula (II) or a therapeutically acceptable salt thereof.
- the present invention provides a compound of formula (III)
- Xaaj is absent or R-(CH 2 ) n -C(O)-, wherein n is an integer from 0 to 8 and R is selected from the group consisting of alkoxy, alkyl, amino, aryl, carboxyl, cycloalkenyl, cycloalkyl, and heterocycle;
- Xaa 2 is selected from the group consisting of D-alanyl, D-alloisoleucyl, allothreonyl, allylglycyl, asparaginyl, aspartyl, glutaminyl, D-glutaminyl, glutamyl, N-methylglutamyl, glycyl, histidyl, homoseryl, D-homoseryl, isoleucyl, D-isoleucyl, lysyl(N-epsilon-acetyl), methionyl, D- methionyl, norleucyl, D-norleucyl, norvalyl, D-norvalyl, D-prolyl, sarcosyl, seryl, D-seryl, N- methylseryl, threonyl, D-threonyl, tryptyl, tyrosyl, and tyros
- Xaa 3 is selected from the group consisting of N-methylalanyl, allothreonyl, arginyl, asparaginyl, D-asparaginyl, citrullyl, glutaminyl, D-glutaminyl, glutamyl, glycyl, homoseryl, leucyl, D-leucyl, lysyl(N-epsilon-acetyl), lysyl(N-epsilon-nicotinyl), norleucyl, norvalyl, D-norvalyl, N- methylnorvalyl, ornithyl(N-delta-acetyl), 3-(3-pyridyl)alanyl, sarcosyl, seryl, D-seryl, N- methylseryl, threonyl, tryptyl, valyl, and N-methyl valyl;
- Xaa 4 is selected from the group consisting of alanyl, alloisoleucyl, aspartyl, citrullyl, isoleucyl, D-isoleucyl, N-methylisoleucyl, leucyl, D-leucyl, lysyl, lysyl(N-epsilon-acetyl), D- lysyl(N-epsilon-acetyl), norvalyl, phenylalanyl, prolyl, D-prolyl, and valyl;
- Xaas is selected from the group consisting of D-alloisoleucyl, arginyl, D-arginyl, citrullyl, histidyl, lysyl, lysyl(N-epsilon-isopropyl), ornithyl, and 3-(3-pyridyl)alanyl;
- Xaa ⁇ is absent or selected from the group consisting of N-methyl-D-alanyl, 2-aminobutyryl, 2-aminoisobutyryl, D-glutaminyl, homoprolyl, hydroxyprolyl, leucyl, phenylalanyl, prolyl, D- prolyl, threonyl, and D-valyl; and
- Xaa is selected from the group consisting of D-alanylamide, azaglycylamide, glycylamide, hydroxyl, D-lysyl(N-epsilon-acetyl)amide, a group represented by the formula
- R is selected from the group consisting of hydrogen, alkyl, cycloalkenyl, and cycloalkyl; R is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocycle, and hydroxyl, with the proviso that when n is 0, R is other than alkoxy or hydroxyl; 3 and R is selected from the group consisting of hydrogen, cycloalkenyl, cycloalkyl, and hydroxyl; provided that when Xaas is D-alloisoleucyl, Xaa 6 is threonyl and Xaa is hydroxyl.
- the present invention provides a compound of formula
- Xaa 2 is selected from the group consisting of threonyl and D-threonyl
- Xaa 3 is selected from the group consisting of norvalyl and D-norvalyl
- Xaa 5 is arginyl
- Xaaj, Xaa-j, Xaa ⁇ and Xaa are as defined for formula (III).
- the present invention provides a compound of formula (III), or a therapeutically acceptable salt thereof, wherein Xaa is selected from the group consisting of allothreonyl, asparaginyl, aspartyl, homoseryl, sarcosyl, and tyrosyl, Xaa 3 is selected from the group consisting of norvalyl and D-norvalyl, Xaas is arginyl, and Xaaj, Xaa , Xaa ⁇ , and Xaa 7 are as defined for formula (III).
- Xaa is selected from the group consisting of allothreonyl, asparaginyl, aspartyl, homoseryl, sarcosyl, and tyrosyl
- Xaa 3 is selected from the group consisting of norvalyl and D-norvalyl
- Xaas is arginyl
- the present invention provides a compound of formula (III), or a therapeutically acceptable salt thereof, wherein Xaa 2 is selected from the group consisting of glutaminyl, glutamyl, N-methylglutamyl, lysyl(N-epsilon-acetyl), methionyl, seryl, and tryptyl, Xaa 3 is selected from the group consisting of norvalyl and D-norvalyl, Xaa ⁇ is arginyl, and Xaaj, Xaa-j, Xaa ⁇ , and Xaa 7 are as defined for formula (III).
- Xaa 2 is selected from the group consisting of glutaminyl, glutamyl, N-methylglutamyl, lysyl(N-epsilon-acetyl), methionyl, seryl, and tryptyl
- Xaa 3 is selected from the group consisting of norvalyl and D-nor
- the present invention provides a compound of formula (III), or a therapeutically acceptable salt thereof, wherein Xaa 3 is selected from the group consisting of glutaminyl and D-glutaminyl, Xaas i arginyl, and Xaaj, Xaa , Xaa 4 , Xaa ⁇ , and Xaa 7 are as defined for formula (III).
- the present invention provides a compound of formula (III), or a therapeutically acceptable salt thereof, wherein Xaa 3 is selected from the group consisting of seryl and D-seryl, Xaas is arginyl, and Xaaj, Xaa 2 , Xaa_ ⁇ , Xaa ⁇ and Xaa are as defined for formula (III).
- the present invention provides a compound of formula (III), or a therapeutically acceptable salt thereof, wherein Xaa 3 is selected from the group consisting of arginyl, asparaginyl, D-asparaginyl, citrullyl, glutamyl, D-leucyl, lysyl(N-epsilon- acetyl), lysyl(N-epsilon-nicotinyl), norleucyl, N-methylnorvalyl, threonyl, and tryptyl, Xaas is arginyl, and Xaaj, Xaa 2 , Xaa , Xaa ⁇ , and Xaa are as defined for formula (III).
- the present invention provides a compound of formula (III), or a therapeutically acceptable salt thereof, wherein Xaas is selected from the group consisting of D-alloisoleucyl, citrullyl, lysyl(N-epsilon-isopropyl), ornithyl, and 3-(3-pyridyl)alanyl, and Xaai, Xaa , Xaa 3 , Xaa_ ⁇ , Xaa ⁇ , and Xaa are as defined for formula (III).
- the present invention provides a pharmaceutical composition comprising a compound of formula (III), or a therapeutically acceptable salt thereof, in combination with a therapeutically acceptable carrier.
- the present invention provides a method of inhibiting angiogenesis in a mammal in recognized need of such treatment comprising administering to the mammal a therapeutically acceptable amount of a compound of formula (III) or a therapeutically acceptable salt thereof.
- the present invention provides a method of treating cancer in a mammal in recognized need of such treatment comprising administering to the mammal a therapeutically acceptable amount of a compound of formula (III) or a therapeutically acceptable salt thereof.
- alkoxy represents an alkyl group attached to the parent molecular moiety through an oxygen atom.
- alkyl represents a monovalent group derived from a straight or branched chain saturated hydrocarbon by the removal of a hydrogen atom.
- Preferred alkyl groups for the present invention are alkyl groups having from one to six carbon atoms (C ⁇ -C 6 alkyl).
- Alkyl groups of one to three carbon atoms (C 1 -C 3 alkyl) are more preferred for the present invention.
- alkylcarbonyl represents an alkyl group attached to the parent molecular moiety through a carbonyl group.
- amino represents -NR a R , wherein R a and R are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
- aryl represents a phenyl group, or a bicyclic or tricyclic fused ring system wherein one or more of the fused rings is a phenyl group.
- Bicyclic fused ring systems are exemplified by a phenyl group fused to a cycloalkenyl group, as defined herein, a cycloalkyl group, as defined herein, or another phenyl group.
- Tricyclic fused ring systems are exemplified by a bicyclic fused ring system fused to a cycloalkenyl group, as defined herein, a cycloalkyl group, as defined herein or another phenyl group.
- aryl include, but are not limited to, anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl.
- the aryl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkyl, carboxyl, halo, and hydroxyl.
- carbonyl represents -C(O)-.
- cycloalkenyl refers to a non-aromatic cyclic or bicyclic ring system having three to ten carbon atoms and one to three rings, wherein each five-membered ring has one double bond, each six-membered ring has one or two double bonds, each seven- and eight- membered ring has one to three double bonds, and each nine-to ten-membered ring has one to four double bonds.
- Examples of cycloalkenyl groups include .cyclohexenyl, octahydronaphthalenyl, norbornylenyl, and the like.
- the cycloalkenyl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkyl, carboxyl, halo, and hydroxyl.
- cycloalkyl refers to a saturated monocyclic, bicyclic, or tricyclic hydrocarbon ring system having three to twelve carbon atoms.
- examples of cycloalkyl groups include cyclopropyl, cyclopentyl, bicyclo[3.1.1]heptyl, adamantyl, and the like.
- the cycloalkyl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkyl, carboxyl, halo, and hydroxyl.
- halo represents F, Cl, Br, or I.
- heterocycle refers to a five-, six-, or seven-membered ring containing one, two, or three heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
- the five-membered ring has zero to two double bonds and the six- and seven-membered rings have zero to three double bonds.
- heterocycle also includes bicyclic groups in which the heterocycle ring is fused to an aryl group, as defined herein.
- the heterocycle groups of the present invention can be attached through a carbon atom or a nitrogen atom in the group.
- heterocycles include, but are not limited to, furyl, thienyl, pyrrolyl, pyrrolidinyl, oxazolyl, thiazolyl, imidazolyl, imidazolinyl, pyrazolyl, isoxazolyl, isothiazolyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, pyridinyl, indolyl, indolinyl, and benzothienyl.
- the heterocycle groups of the present invention can be optionally substituted with one, two, three, or four substituents independently selected from the group consisting of alkoxy, alkyl, carboxyl, halo, and hydroxyl.
- hydroxyl represents -OH.
- terapéuticaally acceptable salt represents salts or zwitterionic forms of the compounds of the present invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.
- the salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid.
- Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydro ⁇ yethansulfonate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2- naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate,trifluoroacetate, phosphate, gluta
- amino groups in the compounds of the present invention can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
- acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
- ⁇ -N-terminus refers to the free ⁇ -amino group of an amino acid in a peptide
- ⁇ -C-terminus refers to the free ⁇ -carboxylic acid terminus of an amino acid in a peptide
- the compounds of the invention possess anti-angiogenic activity.
- angiogenesis inhibitors such compounds are useful in the treatment of both primary and metastatic solid tumors, including carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder and urothelium), female genital tract (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblastic disease), male genital tract (including prostate, seminal vesicles, testes and germ cell tumors), endocrine glands (including the thyroid, adrenal, and pituitary glands), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well as Kaposi's s
- Such compounds may also be useful in treating solid tumors arising from hematopoietic malignancies such as leukemias (i.e., chloromas, plasmacytomas and the plaques and tumors of mycosis fungicides and cutaneous T-cell lymphoma/leukemia) as well as in the treatment of lymphomas (both Hodgkin's and non-Hodgkin's lymphomas).
- leukemias i.e., chloromas, plasmacytomas and the plaques and tumors of mycosis fungicides and cutaneous T-cell lymphoma/leukemia
- lymphomas both Hodgkin's and non-Hodgkin's lymphomas.
- these compounds may be useful in the prevention of metastases from the tumors described above either when used alone or in combination with radiotherapy and/or other chemotherapeutic agents.
- autoimmune diseases such as rheumatoid, immune and degenerative arthritis
- various ocular diseases such as diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, retrolental fibroplasia, neovascular glaucoma, rubeosis, retinal neovascularization due to macular degeneration, hypoxia, angiogenesis in the eye associated with infection or surgical intervention, and other abnormal neovascularization conditions of the eye
- skin diseases such as psoriasis
- blood vessel diseases such as hemagiomas, and capillary proliferation within atherosclerotic plaques
- Osier-Webber Syndrome myocardial angiogenesis
- plaque neovascularization telangiectasia
- hemophiliac joints angiofibroma
- wound granulation such as rheumatoid, immune and degenerative arthritis
- various ocular diseases such as diabetic retinopathy, retinopathy of prematurity
- Other uses include the treatment of diseases characterized by excessive or abnormal stimulation of endothelial cells, including not limited to intestinal adhesions, Crohn's disease, atherosclerosis, scleroderma, and hypertrophic scars, i.e., keloids.
- Another use is as a birth control agent, by inhibiting ovulation and establishment of the placenta.
- the compounds of the invention are also useful in the treatment of diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minutesalia quintos ⁇ ) and ulcers (Helicobacter pylori).
- the compounds of the invention are also useful to reduce bleeding by administration prior to surgery, especially for the treatment of resectable tumors.
- the compounds of the invention may be used in combination with other compositions and procedures for the treatment of diseases.
- a tumor may be treated conventionally with surgery, radiation or chemotherapy combined with a peptide of the present invention and then a peptide of the present invention may be subsequently administered to the patient to extend the dormancy of micrometastases and to stabilize and inhibit the growth of any residual primary tumor.
- the compounds of the invention may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions.
- a sustained-release matrix is a matrix made of materials, usually polymers, which are degradable by enzymatic or acid-base hydrolysis or by dissolution.
- a sustained-release matrix desirably is chosen from biocompatible materials such as liposomes, polylactides (polylactic acid), polyglycolide (polymer of glycolic acid), polylactide co-glycolide (copolymers of lactic acid and glycolic acid) polyanhydrides, poly(ortho)esters, polypeptides, hyaluronic acid, collagen, chondroitin sulfate, carboxylic acids, fatty acids, phospholipids, polysaccharides, nucleic acids, polyamino acids, amino acids such as phenylalanine, tyrosine, isoleucine, polynucleotides, polyvinyl propylene, polyvinylpyrrolidone and silicone.
- a preferred biodegradable matrix is a matrix of one of either polylactide, polyglycolide, or polylactide co-glycolide (co-polymers
- a therapeutically effective amount of one of the compounds of the present invention may be employed in pure form or, where such forms exist, in therapeutically acceptable salt form.
- a “therapeutically effective amount” of the compound of the invention is meant a sufficient amount of the compound to treat an angiogenic disease, (for example, to limit tumor growth or to slow or block tumor metastasis) at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- a compound of the present invention may be administered as pharmaceutical compositions containing the compound of interest in combination with one or more pharmaceutically acceptable excipients.
- a pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- the compositions may be administered parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), rectally, or bucally.
- parenteral refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
- compositions for parenteral injection comprise pharmaceutically-acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
- suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
- Proper fluidity may be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged abso ⁇ tion of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay abso ⁇ tion, such as aluminum monostearate and gelatin.
- adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents.
- Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride,
- Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters), poly(anhydrides), and (poly)glycols, such as PEG. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
- the injectable formulations may be sterilized, for example, by filtration through a bacterial- retaining filter, or by inco ⁇ orating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
- Topical administration includes administration to the skin or mucosa, including surfaces of the lung and eye.
- Compositions for topical administration may be prepared as a dry powder which may be pressurized or non-pressurized.
- the active ingredient in finely divided form may be used in admixture with a larger- sized pharmaceutically-acceptable inert carrier comprising particles having a size, for example, of up to 100 micrometers in diameter.
- suitable inert carriers include sugars such as lactose.
- at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
- the composition may be pressurized and contain a compressed gas, such as nitrogen or a liquefied gas propellant.
- a compressed gas such as nitrogen or a liquefied gas propellant.
- the liquefied propellant medium and indeed the total composition is preferably such that the active ingredient does not dissolve therein to any substantial extent.
- the pressurized composition may also contain a surface active agent, such as a liquid or solid non-ionic surface active agent or may be a solid anionic surface active agent. It is preferred to use the solid anionic surface active agent in the form of a sodium salt.
- a further form of topical administration is to the eye.
- a compound of the invention is delivered in a pharmaceutically acceptable ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, as for example the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/ciliary, lens, choroid/retina and sclera.
- the pharmaceutically-acceptable ophthalmic vehicle may, for example, be an ointment, vegetable oil or an encapsulating material.
- the compounds of the invention may be injected directly into the vitreous and aqueous humour.
- compositions for rectal or vaginal administration are preferably suppositories which may be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Compounds of the present invention may also be administered in the form of liposomes.
- liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium.
- any non-toxic, physiologically-acceptable and metabolizable lipid capable of forming liposomes can be used.
- the present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like.
- the preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.
- the compounds of the invention can be administered as the sole active pharmaceutical agent, they may also be used in combination with one or more agents which are conventionally administered to patients for treating angiogenic diseases.
- the compounds of the invention are effective over the short term to make tumors more sensitive to traditional cytotoxic therapies such as chemicals and radiation.
- the compounds of the invention also enhance the effectiveness of existing cytotoxic adjuvant anti-cancer therapies.
- the compounds of the invention may also be combined with other antiangiogenic agents to enhance their effectiveness, or combined with other antiangiogenic agents and administered together with other cytotoxic agents.
- compounds of the invention when used in the treatment of solid tumors, may be administered with IL-12, retinoids, interferons, angiostatin, endostatin, thalidomide, thrombospondin-1 , thrombospondin-2, captopryl, angioinhibins, TNP-470, pentosan polysulfate, platelet factor 4, LM-609, SU-5416, CM-101, Tecogalan, plasminogen-K-5, vasostatin, vitaxin, vasculostatin, squalamine, marimastat or other MMP inhibitors, anti-neoplastic agents such as alpha inteferon, COMP (cyclophosphamide, vincristine, methotrexate and prednisone), etoposide, mBACOD (methortrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone), PRO
- Total daily dose of the compositions of the invention to be administered to a human or other mammal host in single or divided doses may be in amounts, for example, from 0.0001 to 300 mg/kg body weight daily and more usually 1 to 300 mg/kg body weight.
- agents which can be combined with the compound of the present invention for the inhibition, treatment or prophylaxis of angiogenic diseases are not limited to those listed above, include in principle any agents useful for the treatment or prophylaxis of angiogenic diseases.
- HMVEC human microvascular endothelial
- the HMVEC migration assay was carried out using Human Microvascular Endothelial Cells-Dermal (single donor) and Human Microvascular Endothelial Cells, (neonatal).
- the HMVEC cells were starved overnight in DME containing 0.01 % bovine serum albumin (BSA). Cells were then harvested with trypsin and resuspended in DME with 0.01% BSA at a concentration of 1.5 X 10 6 cells per mL. Cells were added to the bottom of a 48 well modified Boyden chamber (Nucleopore Co ⁇ oration, Cabin John, MD).
- the chamber was assembled and inverted, and cells were allowed to attach for 2 hours at 37 °C to polycarbonate chemotaxis membranes (5 ⁇ m pore size) that had been soaked in 0.01% gelatin overnight and dried.
- the chamber was then reinverted, and test substances (total volume of 50 ⁇ L), including activators, 15 ng/mL bFGF/VEGF, were added to the wells of the upper chamber.
- the apparatus was incubated for 4 hours at 37 °C. Membranes were recovered, fixed and stained (Diff Quick, Fisher Scientific) and the number of cells that had migrated to the upper chamber per 3 high power fields counted. Background migration to DME + 0.1 BSA was subtracted and the data reported as the number of cells migrated per 10 high power fields (400X) or, when results from multiple experiments were combined, as the percent inhibition of migration compared to a positive control.
- Representative compounds described in Examples 1 to 154 inhibited human endothelial cell migration in the above assay by at least 55% when tested at a concentration of 10 nM. More preferred compounds inhibited human endothelial cell migration by approximately 80% to 98% when tested at a concentration of 1 nM, and most preferred compounds inhibited human endothelial cell migration by approximately 55% to 70% when tested at a concentration of 0.01 nM. As shown by these results, the compounds of the present invention demonstrate enhanced potency as compared to previously described antiangiogenic peptides.
- This invention is intended to encompass compounds having formula (I) when prepared by synthetic processes or by metabolic processes. Preparation of the compounds of the invention by metabolic processes include those occurring in the human or animal body (in vivo) or processes occurring in vitro.
- the polypeptides of the present invention may be synthesized by many techniques that are known to those skilled in the art. For solid phase peptide synthesis, a summary of the many techniques may be found in J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, W.H. Freeman Co. (San Francisco), 1963 and J. Meienhofer, Hormonal Proteins and Peptides, vol. 2, p. 46, Academic Press (New York), 1973. For classical solution synthesis see G. Schroder and K. Lupke, The Peptides, vol. 1 , Academic Press (New York), 1965.
- Reagents, resins, amino acids, and amino acid derivatives are commercially available and can be purchased from chem-Impex International, Inc. (Wood Dale, IL, U.S.A.) or Calbiochem- Novabiochem Co ⁇ . (San Diego, CA, U.S.A.) unless otherwise noted herein.
- these methods comprise the sequential addition of one or more amino acids or suitably protected amino acids to a growing peptide chain.
- amino acids or suitably protected amino acids Normally, either the amino or carboxyl group of the first amino acid is protected by a suitable protecting group.
- the protected or derivatized amino acid can then be either attached to an inert solid support or utilized in solution by adding the next amino acid in the sequence having the complimentary (amino or carboxyl) group suitably protected, under conditions suitable for forming the amide linkage.
- the protecting group is then removed from this newly added amino acid residue and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any remaining protecting groups (and any solid support) are removed sequentially or concurrently, to afford the final polypeptide.
- a particularly preferred method of preparing compounds of the present invention involves solid phase peptide synthesis.
- the ⁇ -amino function is protected by an acid or base sensitive group.
- Such protecting groups should have the properties of being stable to the conditions of peptide linkage formation, while being readily removable without destruction of the growing peptide chain or racemization of any of the chiral centers contained therein.
- Suitable protecting groups are 9-fluorenylmethyloxycarbonyl (Fmoc), t-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), biphenylisopropyl-oxycarbonyl, t-amyloxycarbonyl, isobomyloxycarbonyl, ( ⁇ , ⁇ )-dimethyl-3,5-dimethoxybenzyloxycarbonyl, O-nitrophenylsulfenyl, 2- cyano-t-butyloxycarbonyl, and the like.
- the 9-fluorenylmethyloxycarbonyl (Fmoc) protecting group is preferred.
- Particularly preferred side chain protecting groups are: for arginine: N -2,2,5,7,8- pentamethylchroman-6-sulfonyl (Pmc), and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf); for asparagine: trityl (Trt); for aspartic acid: t-butyl (t-Bu); for glutamic acid: tert-butyl ester (O-tBu); for glutamine: trityl (Trt); for N-methylglutamine: t-butyl (t-Bu); for homoserine: trityl (Trt); for histidine: trityl (Trt); for lysine: t-butoxycarbonyl (Boc); for ornithyl: t-butoxycarbonyl (Boc), for penicillamine: trityl (Trt); for serine:
- the C-terminal amino acid is attached to a suitable solid support or resin.
- suitable solid supports useful for the above synthesis are those materials which are inert to the reagents and reaction conditions of the stepwise condensation- deprotection reactions, as well as being insoluble in the media used.
- the preferred solid support for synthesis of C-terminal carboxyl peptides is Sieber amide resin or Sieber ethylamide resin.
- the preferred solid support for C-terminal amide peptides is Sieber ethylamide resin available from Novabiochem Co ⁇ oration.
- the C-terminal amino acid is coupled to the resin by means of a coupling mediated by N,N'- dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC), [0-(7-azabenzotriazol-l- yl)-l ,l ,3,3-tetramethyluronium hexafluorophosphate] (HATU), or 0-benzotriazol-l-yl-N,N,N',N'- tetramethyluroniumhexafluorophosphate (HBTU), with or without 4-dimethylaminopyridine
- DCC dicyclohexylcarbodiimide
- DIC N,N'-diisopropylcarbodiimide
- HATU [0-(7-azabenzotriazol-l- yl)-l ,l ,3,3-tetramethyluronium hexafluorophosphate
- the preferred reagents used in the coupling to the deprotected 4-(2',4'- dimethoxyphenyl-Fmoc-aminomethyl)phenoxyacetamidoethyl resin are O-benzotriazol-1-yl- N,N,N',N'-tetramethyluroniumhexafluorophosphate (HBTU, 1 equiv.) with 1-hydroxybenzotriazole (HOBT, 1 equiv.), or [O-(7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate] (HATU, 1 equiv.) with N-methylmo ⁇ holine (1 equiv.) in DMF.
- HBTU O-benzotriazol-1-yl- N,N,N',N'-tetramethyluroniumhexafluorophosphate
- HOBT 1-hydroxybenzotriazole
- the coupling of successive protected amino acids can be carried out in an automatic polypeptide synthesizer as is well known in the art.
- the ⁇ -amino function in the amino acids of the growing peptide chain are protected with Fmoc.
- the removal of the Fmoc protecting group from the N-terminal side of the growing peptide is accomplished by treatment with a secondary amine, preferably piperidine.
- Each protected amino acid is then introduced in about 3-fold molar excess and the coupling is preferably carried out in DMF.
- the coupling agent is normally t -benzotriazol-l-yl-N,N,N ⁇ N'-tetramethyluroniumhexafluorophosphate (HBTU, 1 equiv.) or [0-(7-azabenzotriazol-l-yl)-l,l ,3,3-tetramethyluronium hexafluorophosphate] (HATU, 1 equiv.) in the presence of N-methylmorpholine (NMM, 1 equiv.).
- the polypeptide is removed from the resin and deprotected, either in succession or in a single operation. Removal of the polypeptide and deprotection can be accomplished in a single operation by treating the resin-bound polypeptide with a cleavage reagent, for example trifluoroacetic acid containing thianisole, water, or ethanedithiol.
- a cleavage reagent for example trifluoroacetic acid containing thianisole, water, or ethanedithiol.
- the resin is cleaved by aminolysis with an alkylamine.
- the peptide may be removed by transesterification, e.g., with methanol, followed by aminolysis or by direct transamidation.
- the protected peptide may be purified at this point or taken to the next step directly.
- the removal of the side chain protecting groups is accomplished using the cleavage cocktail described above.
- the fully deprotected peptide is purified by a sequence of chromatographic steps employing any or all of the following types: ion exchange on a weakly basic resin in the acetate form; hydrophobic adso ⁇ tion chromatography on underivatized polystyrene-divinylbenzene (for example, AMBERLITE ® XAD); silica gel adsorption chromatography; ion exchange chromatography on carboxymethylcellulose; partition chromatography, e.g., on SEPHADEX ® G-25, LH-20 or countercurrent distribution; high performance liquid chromatography (HPLC), especially reverse- phase HPLC on octyl- or octadecylsilyl-silica bonded phase column packing.
- HPLC high performance liquid chromatography
- DMF for N,N- dimethylformamide
- HBTU for O-benzotriazol-l-yl-N,N,N',N'- tetramethyluroniumhexafluorophosphate
- NMM for N-methylmo ⁇ holine
- TFA for trifluoroacetic acid
- NMP for N-methylpyrrolidinone
- HATU for [O-(7-azabenzotriazol-l-yl)-l,l,3,3- tetramethyluronium hexafluorophosphate].
- the peptide was cleaved from the resin using a mixture of (95:2.5:2.5) TFA/anisole/water for 3 hours.
- the peptide solution was concentrated under vacuum and then precipitated with diethyl ether and collected by filtration.
- the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-alloThr(O-tBu) for Fmoc-Thr(O- tBu) in Example 1. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-Gln(Trt) for Fmoc-Nva in Example 1. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-D-alle for Fmoc-D-Ile and Fmoc- Ser(O-tBu) for both Fmoc-Thr(O-tBu) and Fmoc-Nva in Example 1. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-D-alle for Fmoc-D-Ile and Fmoc- Ser(O-tBu) for Fmoc-Nva in Example 1. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 12 N-Ac-D-Ile-Thr-Nva-Ile-Arg-D-ProNHCH 2 CH 2
- the desired product was prepared by substituting Fmoc-D-Pro-Sieber ethylamide resin for Fmoc-Pro-Sieber ethylamide resin in Example 1. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-Gln(Trt) for Fmoc-Thr(O-tBu) in Example 1. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-D-Leu for Fmoc-Ile in Example 1. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 24 N-Ac-D-Ile-Thr-Trp-D-Ile-Arg-ProNHCH 2 CH 2
- the desired product was prepared by substituting Fmoc-T ⁇ (Boc) for Fmoc-Nva and Fmoc- D-Ile for Fmoc-Ile in Example 1.
- the crude peptide was purified by HPLC using a C- 18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-T ⁇ (Boc) for Fmoc-Nva and Fmoc- D-Ala-Sieber amide resin for Fmoc-Pro-Sieber ethylamide resin and adding a coupling with Fmoc- Pro before the coupling with Fmoc-Arg(Pmc) in Example 1.
- the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-Gln(Trt) for Fmoc-Nva and Fmoc- D-Ala-Sieber amide resin for Fmoc-Pro-Sieber ethylamide resin and adding a coupling with Fmoc- Pro before the coupling with Fmoc-Arg(Pmc) in Example 1.
- the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-D-Lys(Ac) for Fmoc-Ile in Example 1. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-D-Pen(Trt) for Fmoc-D-Ile in Example 1. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent mixture varying over 50 minutes in a gradient from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the peptide was cleaved from the resin using a mixture of (95:2.5:2.5) TFA/ani sole/water for 3 hours.
- the peptide solution was concentrated under vacuum and then precipitated with diethyl ether and collected by filtration.
- the crude peptide was purified by HPLC using a C-18 column and with a solvent mixture varying over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-alloThr(O-tBu) for Fmoc-Thr(O- tBu) in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient from 5% to 100% acetonitrile/water containing 0.01 % TFA over 50 minutes.
- the desired product was prepared by substituting Fmoc-Gln(Trt) for Fmoc-Nva in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting 6-methylnicotinic acid for acetic acid in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-Ser(O-tBu) for Fmoc-Thr(O-tBu) and Fmoc-Nva in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 50 N-Ac-Thr-Nva-D-Ile-Arg-ProNHCH CH
- the desired product was prepared by substituting Fmoc-D-Ile for Fmoc-Ile in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 51 N-Ac-Thr-NMeNva-Ile-Arg-ProNHCH CH 2 (SEQ ID NO: 10)
- the desired product was prepared by substituting Fmoc-NMeNva for Fmoc-Nva and using HATU as the activator in the Fmoc-NMeNva coupling in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 56 N-Ac-Ser-Thr-Ile-Arg-ProNHCH 2 CH 2 (SEQ ID NO: 14)
- the desired product was prepared by substituting Fmoc-Ser(O-tBu) for Fmoc -Thr (O-tBu) and Fmoc-Thr(O-tBu) for Fmoc-Nva in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 58 N-Ac-NMeGlu-Nva-Ile-Arg-ProNHCH 2 CH 2 (SEQ ID NO:15)
- the desired product was prepared by substituting Fmoc-NMeGlu(t-Bu) for Fmoc-Thr(O- tBu) and using HATU as activator in the Fmoc -NMeGlu (t-Bu) coupling in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- EXAMPLE 61 N-Ac-Gln-Nva-Ile-Arg-ProNHCH CH 2 (SEQ ID NO: 18)
- the desired product was prepared by substituting Fmoc-Gln(Trt) for Fmoc-Thr(O-tBu) in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 62 N-Ac-alloThr-Ser-Ile-Arg-ProNHCH 2 CH 2 (SEQ ID NO: 19)
- the desired product was prepared by substituting Fmoc-alloThr(O-tBu) for Fmoc-Thr(O- tBu) and Fmoc-Ser(O-tBu) for Fmoc-Nva in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-D-Pro-Sieber ethylamide resin for Fmoc-Pro-Sieber amide resin in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-alloThr(O-tBu) for Fmoc-Thr(O- tBu) and Fmoc-Pro for Fmoc-Ile in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-T ⁇ (Boc) for Fmoc-Thr(O-tBu) in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-Nle for Fmoc-Nva in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-D-Ala-Sieber amide for Fmoc-Pro- Sieber ethylamide and Fmoc-T ⁇ (Boc) for Fmoc-Nva and adding a coupling with Fmoc-Pro before the coupling with Fmoc-Arg(Pmc) in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- EXAMPLE 69 N-Ac-Thr-Ser-He-Arg-Pro-D-AlaNH 2
- the desired product was prepared by substituting Fmoc-D-Ala-Sieber amide resin for Fmoc- Pro-Sieber ethylamide resin and Fmoc-Ser(O-tBu) for Fmoc-Nva and adding a coupling with Fmoc- Pro before the coupling with Fmoc-Arg(Pmc) in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 70 N-Ac-Thr-D-Gln-Ile-Arg-ProNHCH CH
- the desired product was prepared by substituting Fmoc-D-Gln(Trt) for Fmoc-Nva in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- EXAMPLE 74 N-Ac-Thr-Trp-D-Ile-Arg-ProNHCH CH 2
- the desired product was prepared by substituting Fmoc-T ⁇ (Boc) for Fmoc-Nva and Fmoc- D-Ile for Fmoc-Ile in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-Ser(O-tBu) for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and Fmoc-Lys(Ac) for Fmoc-Ile in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-D-Ala-Sieber amide resin for Fmoc- Pro-Sieber ethylamide resin, Fmoc-Ser(O-tBu) for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc- Nva, and adding a coupling with Fmoc-Pro before the coupling with Fmoc-Arg(Pmc) in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 82 N-Ac-D-aTle-Ser-Ser-Nle-Arg-ProNHCH 2 CH 2
- the desired product was prepared by substituting Fmoc-D-alle for Fmoc-D-Ile, Fmoc- Ser(O-tBu) for Fmoc-Thr(O-tBu) and Fmoc-Nva, and Fmoc-Nle for Fmoc-Ile in Example 1.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-D-alle for Fmoc-D-Ile, Fmoc- Ser(O-tBu) for Fmoc-Thr(O-tBu) and Fmoc-Nva, and Fmoc-Nva for Fmoc-Ile in Example 1.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 88 N-Ac-D-aIle-Ser-Ser-Gln-Arg-ProNHCH 2 CH 2
- the desired product was prepared by substituting Fmoc-D-alle for Fmoc-D-Ile, Fmoc- Ser(O-tBu) for Fmoc-Thr(O-tBu) and Fmoc-Nva, and Fmoc-Gln(Trt) for Fmoc-Ile in Example 1. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-D-alle for Fmoc-D-Ile, Fmoc- Ser(O-tBu) for Fmoc-Thr(O-tBu) and Fmoc-Nva, and F oc-Cit for Fmoc-Ile in Example 1.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 92 N-Ac-Thr-Nva-Ile-Orn-ProNHCH 2 CH 2 (SEQ ID NO:27)
- the desired product was prepared by substituting Fmoc-Orn(Boc) for Fmoc-Arg(Pmc) in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-Ser(O-tBu) for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and Fmoc-Nva for Fmoc-Ile in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- EXAMPLE 100 N-Ac-Ser-Gln-Ile-3Pal-ProNHCH 2 CH 2 (SEQ ID NO:35)
- the desired product was prepared by substituting Fmoc-Ser(O-tBu) for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and Fmoc-3Pal for Fmoc-Arg(Pmc) in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 104 H-Thr-Nva-Pro-Arg-ProNHCH 2 CH 2 (SEQ HP NO ⁇ l).
- the desired product was prepared by substituting Fmoc-Pro for Fmoc-Ile and omitting the last acetylation step in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-D-Thr(O-tBu) for Fmoc- Thr(O- tBu) and Fmoc-Pro for Fmoc-Ile in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-D-Pro for Fmoc-Ile in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-Nva for Fmoc-Thr(O-tBu) and Fmoc-Gln(Trt) for Fmoc-Nva in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu) and Fmoc-Pro for Fmoc-Nva in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-Arg(Pmc) for Fmoc-Nva and Fmoc- Cit for Fmoc-Arg(Pmc) in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-Ser(O-tBu) for Fmoc-Nva and Fmoc-Lys(Ac) for Fmoc-Ile in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-D-Ala-Sieber amide resin for Fmoc- Pro-Sieber ethylamide resin, adding a coupling with Fmoc-Pro before the coupling with Fmoc- Arg(Pmc), and substituting Fmoc-Ser(O-tBu) for Fmoc-Nva and Fmoc-Pro for Fmoc-Ile in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 1 14 N-Ac-Thr-Cit-Ile-Arg-ProNHCH 2 CH 2 (SEQ ID NO:43
- the desired product was prepared by substituting Fmoc-Cit for Fmoc-Nva in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- N-.3-MethylvalerylVThr-Nva-He-Arg-ProNHCH CH SEQ ID NO:45
- the desired product was prepared by substituting 3-methylvaleric acid for acetic acid in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu) and Fmoc-Gln(Trt) for Fmoc-Nva in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by coupling with Fmoc- ⁇ -alanine before the coupling with acetic acid in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the desired product was prepared by substituting Fmoc-Gln(Trt) for Fmoc-Nva and coupling with Fmoc- ⁇ -alanine before the coupling with acetic acid in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-Ser(O-tBu) for Fmoc-Thr(O-tBu) and Fmoc-D-Gln(Trt) for Fmoc-Nva in Example 43. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the desired product was prepared by substituting Fmoc-D-Leu for Fmoc-D-Ile and Fmoc- Asp(O-tBu) for Fmoc-Thr(O-tBu) in Example 1. After workup the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- EXAMPLE 129 N-Ac-D-Pro-Gln-Ile-Arg-ProNHCH 2 CH 2
- the desired product was prepared by substituting Fmoc-D-Pro for Fmoc-Thr(O-tBu) and Fmoc-Gln(Trt) for Fmoc-Nva in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- N-Ac-D-Nva-Asn-Ile-Arg-ProNHCH CH The desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu) and Fmoc-Asn(Trt) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N- Ac-D-Nva-Asn-Ile-Arg-ProNHCH 2 CH as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu) and Fmoc-Arg(Pmc) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N- Ac-D-Nva-Arg-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 133 N-Ac-D-Nva-Thr-Ile-Arg-ProNHCH CH 2
- the desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu) and Fmoc-Thr(O-tBu) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N- Ac-D-Nva-Thr-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 134 N-Ac-D-Nva-Ser-Ile-Arg-ProNHCH 2 CH
- the desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu) and Fmoc-Ser(O-tBu) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N- Ac-D-Nva-Ser-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu) and Fmoc-Glu(O-tBu) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N- Ac-D-Nva-Glu-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 136 N-Ac-D-Met-Gln-Ile-Arg-ProNHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-D-Met for Fmoc-Thr(O-tBu) and Fmoc-Gln(Trt) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N- Ac-D-Met-Gln-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- N-Ac-D-Hser-Gln-Ile-Arg-ProNHCH CH 2 The desired product can be prepared by substituting Fmoc-D-Hser(Trf) for Fmoc-Thr(O- tBu) and Fmoc-Gln(Trt) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-Hser-Gln-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu) and Fmoc-Lys(Nic) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N- Ac-D-Nva-Lys(Nic)-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 139 N-Ac-D-Nva-Gln-Lvs(Ac)-Arg-ProNHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and Fmoc-Lys(Ac) for Fmoc-Ile in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-Nva-Gln-Lys(Ac)-Arg-ProNHE as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-D-Ala-Sieber amide resin for Fmoc-Pro-Sieber ethylamide resin, adding a coupling with Fmoc-Pro before the coupling with Fmoc-Arg(Pmc), and substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu) and Fmoc-Gln(Trt) for Fmoc- Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-Nva-Gln-Ile-Arg- Pro-D-AlaNH as the trifluoroacetate salt.
- EXAMPLE 141 N-Ac-D-Nva-Gln-Ile-Cit-ProNHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and Fmoc-Cit for Fmoc-Arg(Pmc) in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-Nva-Gln-Ile-Cit-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 142 N-Ac-D-Nva-Gln-Pro-Arg-ProNHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and Fmoc-Pro for Fmoc-Ile in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-Nva-Gln-Pro-Arg-ProNHE as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and Fmoc-Lys(Isp) for Fmoc-Arg(Pmc) in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-Nva-Gln-Ile-Lys(Isp)-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- Fmoc-Gln(Trt) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N- Ac-D-Nle-Gln-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- N-Ac-Nle-Gln-Ile-Arg-ProNHCH 2 CH 2 (SEQ ID NO:51)
- the desired product can be prepared by substituting Fmoc-Nle for Fmoc-Thr(O-tBu) and Fmoc-Gln(Trt) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N- Ac-Nle-Gln-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and Fmoc-Pro-[4-(4-N-isopropylamino)methyl-3- methoxyphenoxy]butyryl AM resin for Fmoc-Pro Sieber ethylamide resin in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-Nva-Gln-Ile-Arg-ProNHIsp as the trifluoroacetate salt.
- N-.6MeNic -D-Nva-Gln-Ile-Ar g -ProNHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-D-Nva for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and 6-methylnicotinic acid for acetic acid in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-(6MeNic)-D-Nva-Gln-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-Nva for Fmoc-Thr(O-tBu) and Fmoc-D-Gln(Trt) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N- Ac-Nva-D-Gln-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 149 N-Ac-Nva-D-Asn-Ile-Arg-ProNHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-Nva for Fmoc-Thr(O-tBu) and Fmoc-D-Asn(Trt) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N- Ac-Nva-D-Asn-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- N-Ac-Nva-D-Ser-Ile-Arg-ProNHCH 2 CH 2 The desired product can be prepared by substituting Fmoc-Nva for Fmoc-Thr(O-tBu) and Fmoc-D-Ser(O-tBu) for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N-Ac-Nva-D-Ser-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 151 N-Ac-Nva-D-Leu-Ile-Arg-ProNHCH 2 CH
- the desired product can be prepared by substituting Fmoc-Nva for Fmoc-Thr(O-tBu) and Fmoc-D-Leu for Fmoc-Nva in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N- Ac-Nva-D-Leu-Ile-Arg-ProNHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 153 N-Ac-Thr-Gln-Ile-Arg-NHCH 2 CH 2 (SEQ ID NO:52)
- the desired product was prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Gln(Trt) for Fmoc-Nva, and omitting the coupling with Fmoc-Arg(Pmc) in Example 43.
- EXAMPLE 154 N-Ac-Thr-Nva-Ile-Arg-NHCH 2 CH 2 (SEQ ID NO:53
- the desired product was prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxy.butyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin and omitting the coupling with Fmoc-Arg(Pmc) in Example 43.
- the crude peptide was purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- EXAMPLE 155 N-Ac-D-Ile-Thr-Gln-Ile-Arg-NHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Gln(Trt) for Fmoc-Nva, and omitting the coupling with Fmoc-Arg(Pmc) in Example 1.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-Ile-Thr-Gln-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt
- EXAMPLE 156 N-Ac-D-Ile-Thr-Nva-Lvs.Ac -Arg-NHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Lys(Ac) for Fmoc-Ile, and omitting the coupling with Fmoc-Arg(Pmc) in Example 1.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-IleThr-Nva-Lys(Ac)-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 157 N-Ac-D-He-Ser-Gln-Ile-Arg-NHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Ser(O-tBu) for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and omitting the coupling with Fmoc-Arg(Pmc) in Example 1.
- the crude peptide can be purified by HPLC using a C- 18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N-Ac-D- Ile-Ser-Gln-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 158 N-Ac-D-aIle-Ser-Ser-Ile-Arg-NHCH CH 2
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- D-alle for Fmoc-D-Ile, Fmoc-Ser(O-tBu) for Fmoc-Thr(O-tBu) and Fmoc-Nva, and omitting the coupling with Fmoc-Arg(Pmc) in Example 1.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N- Ac-D-aIle-Ser-Ser-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 159 N-Ac-D-aIle-Thr-Nva-He-Arg-NHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxy.butyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- D-alle for Fmoc-D-Ile, and omitting the coupling with Fmoc-Arg(Pmc) in Example 1.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-aIle-Thr-Nva-Ile-Arg-NHCH CH 3 as the trifluoroacetate salt.
- EXAMPLE 160 N-Ac-D-Ile-Thr-Gln-Lvs( ⁇ cVArg-NHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Gln(Trt) for Fmoc-Nva, Fmoc-Lys(Ac) for Fmoc-Ile, and omitting the coupling with Fmoc- Arg(Pmc) in Example 1.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-D- He-Thr-Gln-Lys(Ac)-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 161 N-Ac-D-aIle-Ser-Nva-Lvs( ⁇ cVArg-NHCH CH 2
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- D-alle for Fmoc-D-Ile, Fmoc-Ser(O-tBu) for Fmoc-Thr(O-tBu), Fmoc-Lys(Ac) for Fmoc-Ile, and omitting the coupling with Fmoc-Arg(Pmc) in Example 1.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-aIle-Ser-Nva-Lys(Ac)-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Ser(O-tBu) for Fmoc-Nva, and omitting the coupling with Fmoc-Arg(Pmc) in Example 1.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-D-Ile-Thr-Ser-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- NMeNva for Fmoc-Nva, omitting the coupling with Fmoc-Arg(Pmc), and using HATU instead of HBTU in the coupling of the N-methyl-amino acid in Example 1.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide.N-Ac-D-Ile-Thr-NMeNva-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Ser(O-tBu) for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and omitting the coupling with Fmoc-Arg(Pmc) in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N-Ac- Ser-Gln-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Ser(O-tBu) for Fmoc-Thr(O-tBu) and Fmoc-Nva, and omitting the coupling with Fmoc-Arg(Pmc) in Example 43
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-Ser-Ser-Ile-Arg-NHCH 2 CH 3 as the tri
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Lys(Ac) for Fmoc-Ile, and omitting the coupling with Fmoc-Arg(Pmc) in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-Thr-Nva-Lys(Ac)-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Gln(Trt) for Fmoc-Nva, Fmoc-Lys(Ac) for Fmoc-Ile, and omitting the coupling with Fmoc- Arg(Pmc) in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac- Thr-Gln-Lys(Ac)-Arg-NHCH 2 CH 3 as the trifluoroacetate salt
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Ser(O-tBu) for Fmoc-Nva, and omitting the coupling with Fmoc-Arg(Pmc) in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide N-Ac-Thr-Ser-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Met for Fmoc-Thr(O-tBu), and omitting the coupling with Fmoc-Arg(Pmc) in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-Met-Nva-Ile-Arg-NHCH CH 3 as the trifluoroacetate salt.
- EXAMPLE 170 N-Ac-Thr-NMeNva-Ile-Arg-NHCH 2 CH 2 (SEQ ID NO:60).
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxy.butyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin and Fmoc-NMeNva for Fmoc-Nva, omitting the coupling with Fmoc-Arg(Pmc), and using HATU instead of HBTU in the coupling of the N-methyl-amino acid in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Thr-NMeNva-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 171 N-Ac-D-Nva-Gln-He-Arg-NHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- D-Nva for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and omitting the coupling with Fmoc- Arg(Pmc) in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide NAc-D- Nva-Gln-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 172 N-Ac-Ser-Nva-Ile-Arg-NHCH 2 CH 2 (SEQ ID NO:6n
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- Ser(O-tBu) for Fmoc-Thr(O-tBu), and omitting the coupling with Fmoc-Arg(Pmc) in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide N-Ac-Ser-Nva-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 173 N-Ac-D-Thr-Gln-He-Arg-NHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- D-Thr(O-tBu) for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and omitting the coupling with Fmoc-Arg(Pmc) in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01 % TFA.
- the pure fractions can be lyophilized to provide.N-Ac-D- Thr-Gln-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
- EXAMPLE 174 N-Ac-D-Ser-Gln-Ile-Arg-NHCH 2 CH 2
- the desired product can be prepared by substituting Fmoc-Arg(Pbf)-[4-(4-N-ethyl)methyl-3- methoxyphenoxyjbutyryl AM resin ethylamide resin for Fmoc-Pro Sieber ethylamide resin, Fmoc- DSer(O-tBu) for Fmoc-Thr(O-tBu), Fmoc-Gln(Trt) for Fmoc-Nva, and omitting the coupling with Fmoc-Arg(Pmc) in Example 43.
- the crude peptide can be purified by HPLC using a C-18 column and a solvent system varying in gradient over 50 minutes from 5% to 100% acetonitrile/water containing 0.01% TFA.
- the pure fractions can be lyophilized to provide_N-Ac-D- Ser-Gln-Ile-Arg-NHCH 2 CH 3 as the trifluoroacetate salt.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US263811 | 1988-10-28 | ||
US540 | 1995-06-27 | ||
US7 | 2001-10-31 | ||
US10/000,711 US20030105025A1 (en) | 2001-10-31 | 2001-10-31 | Tri-and tetrapeptides having antiangiogenic activity |
US10/000,540 US20030119745A1 (en) | 2001-10-31 | 2001-10-31 | HEXA- and heptapeptides having antiangiogenic activity |
US10/263,811 US20030105022A1 (en) | 2001-10-31 | 2002-10-04 | Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity |
PCT/US2002/034760 WO2003037266A2 (en) | 2001-10-31 | 2002-10-30 | Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1451209A2 true EP1451209A2 (en) | 2004-09-01 |
EP1451209A4 EP1451209A4 (en) | 2009-06-03 |
Family
ID=32659830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02789322A Withdrawn EP1451209A4 (en) | 2001-10-31 | 2002-10-30 | Tetra-,penta-,hexa- and heptapeptides having antiangiogenic activity |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1451209A4 (en) |
JP (1) | JP2005512980A (en) |
CA (1) | CA2466152A1 (en) |
MX (1) | MXPA04004135A (en) |
UY (1) | UY27523A1 (en) |
WO (1) | WO2003037266A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030125260A1 (en) * | 2001-10-31 | 2003-07-03 | Fortuna Haviv | Tetra-and pentapeptides having antiangiogenic activity |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780426A (en) * | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
US5932545A (en) * | 1997-03-17 | 1999-08-03 | Abbott Laboratories | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1078002B1 (en) * | 1998-05-22 | 2008-05-21 | Abbott Laboratories | Peptide antiangiogenic drugs |
-
2002
- 2002-10-30 CA CA002466152A patent/CA2466152A1/en not_active Abandoned
- 2002-10-30 JP JP2003539612A patent/JP2005512980A/en active Pending
- 2002-10-30 WO PCT/US2002/034760 patent/WO2003037266A2/en active Application Filing
- 2002-10-30 EP EP02789322A patent/EP1451209A4/en not_active Withdrawn
- 2002-10-30 MX MXPA04004135A patent/MXPA04004135A/en unknown
- 2002-10-30 UY UY27523A patent/UY27523A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780426A (en) * | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
US5932545A (en) * | 1997-03-17 | 1999-08-03 | Abbott Laboratories | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
Non-Patent Citations (2)
Title |
---|
MIYASAKI KT ET AL: "Bactericidal Activities of Synthetic Human Leukocyte Cathepsin G-Derived Antibiotic Peptides and Congeners against Actinobacillus actinomycetemcomitans and Capnocytophaga sputigena" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 37, no. 12, December 1993 (1993-12), pages 2710-2715, XP002523772 * |
See also references of WO03037266A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2466152A1 (en) | 2003-05-08 |
WO2003037266A3 (en) | 2003-12-11 |
MXPA04004135A (en) | 2004-07-08 |
UY27523A1 (en) | 2003-05-30 |
EP1451209A4 (en) | 2009-06-03 |
WO2003037266A2 (en) | 2003-05-08 |
JP2005512980A (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030125260A1 (en) | Tetra-and pentapeptides having antiangiogenic activity | |
US20050215484A1 (en) | Di-, tri-, and tetra-peptides having antiangiogenic activity | |
EP1232183B1 (en) | Peptides having antiangiogenic activity | |
EP1242455A1 (en) | N-alkylated peptides having antiangiogenic activity | |
US20060194737A1 (en) | Hepta-, octa-and nonapeptides having antiangiogenic activity | |
US6777535B1 (en) | N-alkylated peptides having antiangiogenic activity | |
US7169888B2 (en) | Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity | |
US7037897B2 (en) | TRI-, TETRA-, and penta-peptides having antiangiogenic activity | |
US7122625B2 (en) | Hexa-, hepta-, and octapeptides having antiangiogenic activity | |
US20030105022A1 (en) | Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity | |
EP2177530B1 (en) | Octapeptide having antiangiogenic activity | |
US20030105025A1 (en) | Tri-and tetrapeptides having antiangiogenic activity | |
CA2466170C (en) | Hexa-, hepta-, and octapeptides having antiangiogenic activity | |
US6753408B1 (en) | Peptides having antiangiogenic activity | |
EP1451209A2 (en) | Tetra-,penta-,hexa- and heptapeptides having antiangiogenic activity | |
US20030119745A1 (en) | HEXA- and heptapeptides having antiangiogenic activity | |
US20030125261A1 (en) | Penta- and hexapeptides having antiangiogenic activity | |
US20030119746A1 (en) | Hepta-and octapeptides having antiangiogenic activity | |
AU2002353929A1 (en) | Hepta-, octa- and nonapeptides having antiangiogenic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040528 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1068900 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090506 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090805 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1068900 Country of ref document: HK |